Steven N. Liss, Vice-Principal (Research), Queen’s University, and Chair, Board of Directors, PARTEQ Innovations, is pleased to announce Dr. Jim Banting (BScH’93, PhD’97) as the new president and chief executive officer of PARTEQ Innovations.
Dr. Banting has more than 15 years of business development experience in the life science sector. He was most recently the head of business development at Sigma-Tau Pharmaceuticals, located in the Washington D.C. area. Previously, Dr. Banting spent six years in the business development group of the U.S. biotechnology company Human Genome Sciences. He began his career as a co-founder of the Queen’s spin-off company Vaxis Therapeutics.
PARTEQ Innovations was founded in 1987 by Queen’s University at Kingston, Ontario, Canada to commercialize intellectual property arising from university-generated research. PARTEQ provides institutional researchers with the business, intellectual property, and financial expertise that is needed to advance their discoveries to the public.